The implementation of a test that assesses the expression of hormone receptors and enables an appropriate therapy decision [3] was, besides testing for the human epidermal growth factor receptor 2 (HER2) and a subsequent trastuzumab treatment [4], the beginning of individualized therapies for BC patients. This evidence concerns the gene NR4A1 and breast cancer.